Evidence map›Paper›PMID 41229976›Full record

ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2025

High-risk extranodal natural killer/T-cell lymphoma patients could benefit more from allogeneic hematopoietic stem cell transplantation as consolidation: A real-world multicenter analysis in China.

Yuewen Wang, Yi Xia, Zhenyang Gu, Yu Chang, Lei Yang, Peipei Yang, Yanmin Zhao, Chunli Zhang, Na Wang, Shenmiao Yang and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Yuewen Wang *Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.
Yi Xia *Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.
Zhenyang Gu *Chief Department of Hematology, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China.
Yu Chang *Department of Hematology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Lei Yang *Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100005, China.
Peipei Yang *Department of Hematology, West China Hospital, Sichuan University, Chengdu 610041, China.
Yanmin Zhao *Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
Chunli Zhang *Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
Na Wang *Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Shenmiao YangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.
Yang YangDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Chuanhe JiangState Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Leqing CaoPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.
Daoxing DengPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.
Haiyang LuState Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Fengrong WangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.
Mingzhi ZhangDepartment of Hematology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Yang CaoDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Xiaoxia HuState Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Ting NiuDepartment of Hematology, West China Hospital, Sichuan University, Chengdu 610041, China.
Xiaodong MoPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Both allogeneic hematopoietic stem cell transplantation (allo-HSCT) and autologous HSCT (ASCT) are important therapies for extranodal natural killer/T-cell lymphoma (ENKTCL); however, no large-scale, multicenter study has compared the efficacy and safety between allo-HSCT and ASCT in these patients. Our multicenter, real-world study aimed to evaluate the outcomes of allo-HSCT Methods: This was a multicenter, retrospective study with nine hospitals in China, and 114 patients with ENKTCL were enrolled. Sixty patients received ASCT and 54 received allo-HSCT. The primary outcome was progression-free survival (PFS). In the sensitivity analysis, propensity score matching (PSM) analyses were conducted to adjust for baseline prognostic factors. Landmark analysis were conducted to minimize immortal-time bias. Results: Patients in the allo-HSCT group presented with more adverse prognostic factors. Allo-HSCT group showed a significantly better PFS and a lower disease progression rate compared with ASCT group in patients with Ann Arbor stage III/IV disease (PFS: 100% Conclusions: ENKTCL patients with high-risk characteristics could benefit more from allo-HSCT as consolidation.

Indexed as

allogeneic hematopoietic stem cell transplantationautologous hematopoietic stem cell transplantationconsolidation therapyExtranodal natural killer/T-cell lymphomahigh-risk disease

Identifiers

PMID41229976
PMCPMC12603627

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.